taurine has been researched along with Genetic Predisposition in 8 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We genotyped 31 diabetes-associated variants to calculate a genetic risk score (GRS) and measured plasma taurine levels and glycemic traits among participants from the Preventing Overweight Using Novel Dietary Strategies (POUNDS Lost) trial." | 9.22 | Plasma Taurine, Diabetes Genetic Predisposition, and Changes of Insulin Sensitivity in Response to Weight-Loss Diets. ( Bray, GA; Ceglarek, U; Heianza, Y; Huang, T; Ma, W; Qi, L; Sacks, FM; Thiery, J; Wang, T; Zheng, Y, 2016) |
| "The prevalence of type 2 diabetes mellitus (T2DM) is increasing with an epidemic growth rate." | 6.71 | Effect of taurine treatment on insulin secretion and action, and on serum lipid levels in overweight men with a genetic predisposition for type II diabetes mellitus. ( Brøns, C; Dyerberg, J; Spohr, C; Storgaard, H; Vaag, A, 2004) |
| "We genotyped 31 diabetes-associated variants to calculate a genetic risk score (GRS) and measured plasma taurine levels and glycemic traits among participants from the Preventing Overweight Using Novel Dietary Strategies (POUNDS Lost) trial." | 5.22 | Plasma Taurine, Diabetes Genetic Predisposition, and Changes of Insulin Sensitivity in Response to Weight-Loss Diets. ( Bray, GA; Ceglarek, U; Heianza, Y; Huang, T; Ma, W; Qi, L; Sacks, FM; Thiery, J; Wang, T; Zheng, Y, 2016) |
| "The aim of this study was to evaluate the beta-endorphin (beta-endorphin) plasma level in Warsaw Low Preferring (WLP) and Warsaw high-preferring (WHP) rats after repeated administration of acamprosate, one of most effective drug in the treatment of alcoholism." | 3.73 | Changes in the beta-endorphin plasma level after repeated treatment with acamprosate in rats selectively bred for high and low alcohol preference. ( Cwiek, W; Czarnecka, E; Dyr, W; Zalewska-Kaszubska, J, 2005) |
| "The prevalence of type 2 diabetes mellitus (T2DM) is increasing with an epidemic growth rate." | 2.71 | Effect of taurine treatment on insulin secretion and action, and on serum lipid levels in overweight men with a genetic predisposition for type II diabetes mellitus. ( Brøns, C; Dyerberg, J; Spohr, C; Storgaard, H; Vaag, A, 2004) |
| "Tramiprosate is a small-molecule Aβ anti-aggregation agent that was evaluated in phase III clinical trials for AD but did not meet the primary efficacy endpoints; however, a pre-specified subgroup analysis revealed robust, sustained, and clinically meaningful cognitive and functional effects in patients with AD homozygous for the ε4 allele of apolipoprotein E4 (APOE4/4 homozygotes), who carry an increased risk for the disease." | 1.46 | Elucidating the Aβ42 Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimer's Disease: Integrating Molecular Analytical Methods, Pharmacokinetic and Clinical Data. ( Blennow, K; Fillit, H; Hey, JA; Kocis, P; Ray, S; Sinko, W; Tolar, M; Yu, J, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kocis, P | 1 |
| Tolar, M | 1 |
| Yu, J | 1 |
| Sinko, W | 1 |
| Ray, S | 1 |
| Blennow, K | 1 |
| Fillit, H | 1 |
| Hey, JA | 1 |
| Hobert, JA | 1 |
| Embacher, R | 1 |
| Mester, JL | 1 |
| Frazier, TW | 1 |
| Eng, C | 1 |
| Karpyak, VM | 1 |
| Biernacka, JM | 1 |
| Geske, JR | 1 |
| Jenkins, GD | 1 |
| Cunningham, JM | 1 |
| Rüegg, J | 1 |
| Kononenko, O | 1 |
| Leontovich, AA | 1 |
| Abulseoud, OA | 1 |
| Hall-Flavin, DK | 1 |
| Loukianova, LL | 1 |
| Schneekloth, TD | 1 |
| Skime, MK | 1 |
| Frank, J | 1 |
| Nöthen, MM | 1 |
| Rietschel, M | 1 |
| Kiefer, F | 2 |
| Mann, KF | 1 |
| Weinshilboum, RM | 1 |
| Frye, MA | 1 |
| Choi, DS | 1 |
| Zheng, Y | 1 |
| Ceglarek, U | 1 |
| Huang, T | 1 |
| Wang, T | 1 |
| Heianza, Y | 1 |
| Ma, W | 1 |
| Bray, GA | 1 |
| Thiery, J | 1 |
| Sacks, FM | 1 |
| Qi, L | 1 |
| Brøns, C | 1 |
| Spohr, C | 1 |
| Storgaard, H | 1 |
| Dyerberg, J | 1 |
| Vaag, A | 1 |
| Zalewska-Kaszubska, J | 1 |
| Cwiek, W | 1 |
| Dyr, W | 1 |
| Czarnecka, E | 1 |
| Jiménez-Arriero, MA | 1 |
| Klein, O | 1 |
| Diehl, A | 1 |
| Rubio, G | 1 |
| Rockel, N | 1 |
| Esser, C | 1 |
| Grether-Beck, S | 1 |
| Warskulat, U | 1 |
| Flögel, U | 1 |
| Schwarz, A | 1 |
| Schwarz, T | 1 |
| Yarosh, D | 1 |
| Häussinger, D | 1 |
| Krutmann, J | 1 |
2 trials available for taurine and Genetic Predisposition
| Article | Year |
|---|---|
Plasma Taurine, Diabetes Genetic Predisposition, and Changes of Insulin Sensitivity in Response to Weight-Loss Diets.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Diet, Reducing; Female; Genetic Predisposition to Disease; G | 2016 |
Effect of taurine treatment on insulin secretion and action, and on serum lipid levels in overweight men with a genetic predisposition for type II diabetes mellitus.
Topics: Adult; Aged; Cross-Over Studies; Diabetes Mellitus, Type 2; Dietary Supplements; Double-Blind Method | 2004 |
6 other studies available for taurine and Genetic Predisposition
| Article | Year |
|---|---|
Elucidating the Aβ42 Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimer's Disease: Integrating Molecular Analytical Methods, Pharmacokinetic and Clinical Data.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Apolipoprotein E4; Dose-Response Relationship, Drug; Drug | 2017 |
Biochemical screening and PTEN mutation analysis in individuals with autism spectrum disorders and macrocephaly.
Topics: Adolescent; Adult; Aspartic Acid; Child; Child Development Disorders, Pervasive; Child, Preschool; C | 2014 |
Genetic markers associated with abstinence length in alcohol-dependent subjects treated with acamprosate.
Topics: Acamprosate; Adolescent; Adult; Aged; Aged, 80 and over; Alcohol Deterrents; Alcoholism; Female; Gen | 2014 |
Changes in the beta-endorphin plasma level after repeated treatment with acamprosate in rats selectively bred for high and low alcohol preference.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Induced Disorders, Nervous System; Alcoholism; Animals; bet | 2005 |
Cloninger's typology and treatment outcome in alcohol-dependent subjects during pharmacotherapy with naltrexone.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Combined Modality Therapy; Double-Blind Method; | 2008 |
The osmolyte taurine protects against ultraviolet B radiation-induced immunosuppression.
Topics: Animals; Cells, Cultured; DNA Repair; Female; Genetic Predisposition to Disease; Immunosuppression T | 2007 |